#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Functional	_
1-2	11-21	Connectome	_
1-3	22-34	Organization	_
1-4	35-43	Predicts	_
1-5	44-54	Conversion	_
1-6	55-57	to	_
1-7	58-67	Psychosis	_
1-8	68-70	in	_
1-9	71-79	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-10	80-89	High-Risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-11	90-95	Youth	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
1-12	96-100	from	_
1-13	101-104	the	_
1-14	105-110	SHARP	_
1-15	111-118	Program	_
1-16	119-122	The	_
1-17	123-132	emergence	_
1-18	133-135	of	_
1-19	136-145	prodromal	_
1-20	146-154	symptoms	_
1-21	155-157	of	_
1-22	158-171	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-23	172-175	and	_
1-24	176-181	their	_
1-25	182-191	evolution	_
1-26	192-196	into	_
1-27	197-202	overt	_
1-28	203-212	psychosis	_
1-29	213-216	may	_
1-30	217-221	stem	_
1-31	222-226	from	_
1-32	227-229	an	_
1-33	230-238	aberrant	_
1-34	239-249	functional	_
1-35	250-264	reorganization	_
1-36	265-267	of	_
1-37	268-271	the	_
1-38	272-277	brain	_
1-39	278-284	during	_
1-40	285-296	adolescence	_
1-41	297-298	.	_

2-1	299-301	To	_
2-2	302-309	examine	_
2-3	310-317	whether	_
2-4	318-331	abnormalities	_
2-5	332-334	in	_
2-6	335-345	connectome	_
2-7	346-358	organization	_
2-8	359-366	precede	_
2-9	367-376	psychosis	_
2-10	377-382	onset	_
2-11	383-384	,	_
2-12	385-387	we	_
2-13	388-397	performed	_
2-14	398-399	a	_
2-15	400-410	functional	_
2-16	411-421	connectome	_
2-17	422-430	analysis	_
2-18	431-433	in	_
2-19	434-435	a	_
2-20	436-441	large	_
2-21	442-448	cohort	_
2-22	449-451	of	_
2-23	452-468	medication-naïve	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus
2-24	469-474	youth	_
2-25	475-477	at	_
2-26	478-482	risk	_
2-27	483-486	for	_
2-28	487-496	psychosis	_
2-29	497-501	from	_
2-30	502-505	the	_
2-31	506-514	Shanghai	_
2-32	515-517	At	_
2-33	518-522	Risk	_
2-34	523-526	for	_
2-35	527-536	Psychosis	_
2-36	537-538	(	_
2-37	539-544	SHARP	_
2-38	545-546	)	_
2-39	547-552	study	_
2-40	553-554	.	_

3-1	555-558	The	_
3-2	559-564	SHARP	_
3-3	565-572	program	_
3-4	573-575	is	_
3-5	576-577	a	_
3-6	578-590	longitudinal	_
3-7	591-596	study	_
3-8	597-599	of	_
3-9	600-611	adolescents	_
3-10	612-615	and	_
3-11	616-621	young	_
3-12	622-628	adults	_
3-13	629-631	at	_
3-14	632-640	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-15	641-645	High	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-16	646-650	Risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-17	651-652	(	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-18	653-656	CHR	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-19	657-658	)	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
3-20	659-662	for	_
3-21	663-672	psychosis	_
3-22	673-674	,	_
3-23	675-684	conducted	_
3-24	685-687	at	_
3-25	688-691	the	_
3-26	692-700	Shanghai	_
3-27	701-707	Mental	_
3-28	708-714	Health	_
3-29	715-721	Center	_
3-30	722-724	in	_
3-31	725-738	collaboration	_
3-32	739-743	with	_
3-33	744-756	neuroimaging	_
3-34	757-769	laboratories	_
3-35	770-772	at	_
3-36	773-780	Harvard	_
3-37	781-784	and	_
3-38	785-788	MIT	_
3-39	789-790	.	_

4-1	791-794	Our	_
4-2	795-800	study	_
4-3	801-809	involved	_
4-4	810-811	a	_
4-5	812-817	total	_
4-6	818-820	of	_
4-7	821-824	251	_
4-8	825-833	subjects	_
4-9	834-835	,	_
4-10	836-845	including	_
4-11	846-849	158	_
4-12	850-854	CHRs	_
4-13	855-858	and	_
4-14	859-861	93	_
4-15	862-866	age-	_
4-16	867-868	,	_
4-17	869-873	sex-	_
4-18	874-875	,	_
4-19	876-879	and	_
4-20	880-897	education-matched	_
4-21	898-905	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-22	906-914	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
4-23	915-916	.	_

5-1	917-923	During	_
5-2	924-932	one-year	_
5-3	933-942	follow-up	_
5-4	943-944	,	_
5-5	945-947	23	_
5-6	948-952	CHRs	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
5-7	953-962	developed	_
5-8	963-972	psychosis	_
5-9	973-974	.	_

6-1	975-979	CHRs	_
6-2	980-983	who	_
6-3	984-989	would	_
6-4	990-992	go	_
6-5	993-995	on	_
6-6	996-998	to	_
6-7	999-1006	develop	_
6-8	1007-1016	psychosis	_
6-9	1017-1021	were	_
6-10	1022-1027	found	_
6-11	1028-1030	to	_
6-12	1031-1035	show	_
6-13	1036-1044	abnormal	_
6-14	1045-1052	modular	_
6-15	1053-1063	connectome	_
6-16	1064-1076	organization	_
6-17	1077-1079	at	_
6-18	1080-1088	baseline	_
6-19	1089-1090	,	_
6-20	1091-1096	while	_
6-21	1097-1100	CHR	_
6-22	1101-1115	non-converters	_
6-23	1116-1119	did	_
6-24	1120-1123	not	_
6-25	1124-1125	.	_

7-1	1126-1128	In	_
7-2	1129-1132	all	_
7-3	1133-1137	CHRs	_
7-4	1138-1139	,	_
7-5	1140-1148	abnormal	_
7-6	1149-1156	modular	_
7-7	1157-1167	connectome	_
7-8	1168-1180	organization	_
7-9	1181-1183	at	_
7-10	1184-1192	baseline	_
7-11	1193-1196	was	_
7-12	1197-1207	associated	_
7-13	1208-1212	with	_
7-14	1213-1214	a	_
7-15	1215-1225	three-fold	_
7-16	1226-1236	conversion	_
7-17	1237-1241	rate	_
7-18	1242-1243	.	_

8-1	1244-1245	A	_
8-2	1246-1261	region-specific	_
8-3	1262-1270	analysis	_
8-4	1271-1277	showed	_
8-5	1278-1282	that	_
8-6	1283-1288	brain	_
8-7	1289-1296	regions	_
8-8	1297-1307	implicated	_
8-9	1308-1310	in	_
8-10	1311-1323	early-course	_
8-11	1324-1337	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-12	1338-1339	,	_
8-13	1340-1349	including	_
8-14	1350-1358	superior	_
8-15	1359-1367	temporal	_
8-16	1368-1373	gyrus	_
8-17	1374-1377	and	_
8-18	1378-1386	anterior	_
8-19	1387-1396	cingulate	_
8-20	1397-1403	cortex	_
8-21	1404-1405	,	_
8-22	1406-1410	were	_
8-23	1411-1415	most	_
8-24	1416-1424	abnormal	_
8-25	1425-1427	in	_
8-26	1428-1433	terms	_
8-27	1434-1436	of	_
8-28	1437-1444	modular	_
8-29	1445-1455	assignment	_
8-30	1456-1457	.	_

9-1	1458-1461	Our	_
9-2	1462-1469	results	_
9-3	1470-1474	show	_
9-4	1475-1479	that	_
9-5	1480-1490	functional	_
9-6	1491-1498	changes	_
9-7	1499-1501	in	_
9-8	1502-1507	brain	_
9-9	1508-1515	network	_
9-10	1516-1528	organization	_
9-11	1529-1536	precede	_
9-12	1537-1540	the	_
9-13	1541-1546	onset	_
9-14	1547-1549	of	_
9-15	1550-1559	psychosis	_
9-16	1560-1563	and	_
9-17	1564-1567	may	_
9-18	1568-1573	drive	_
9-19	1574-1583	psychosis	_
9-20	1584-1595	development	_
9-21	1596-1598	in	_
9-22	1599-1606	at-risk	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
9-23	1607-1612	youth	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
9-24	1613-1614	.	_

10-1	1615-1624	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-2	1625-1628	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-3	1629-1636	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
10-4	1637-1649	Participants	_
10-5	1650-1654	This	_
10-6	1655-1660	study	_
10-7	1661-1669	involved	_
10-8	1670-1671	a	_
10-9	1672-1677	total	_
10-10	1678-1680	of	_
10-11	1681-1684	251	_
10-12	1685-1697	participants	_
10-13	1698-1699	,	_
10-14	1700-1709	including	_
10-15	1710-1713	158	_
10-16	1714-1722	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-17	1723-1727	High	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-18	1728-1732	Risk	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-19	1733-1734	(	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-20	1735-1738	CHR	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-21	1739-1740	)	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-22	1741-1749	subjects	http://maven.renci.org/NeuroBridge/neurobridge#ClinicalRiskStatus
10-23	1750-1753	and	_
10-24	1754-1756	93	_
10-25	1757-1764	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-26	1765-1773	Controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-27	1774-1775	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-28	1776-1778	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-29	1779-1780	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
10-30	1781-1788	matched	_
10-31	1789-1791	to	_
10-32	1792-1796	CHRs	_
10-33	1797-1802	based	_
10-34	1803-1805	on	_
10-35	1806-1809	age	_
10-36	1810-1811	,	_
10-37	1812-1815	sex	_
10-38	1816-1817	,	_
10-39	1818-1821	and	_
10-40	1822-1831	education	_
10-41	1832-1834	in	_
10-42	1835-1840	years	_
10-43	1841-1842	.	_

11-1	1843-1846	The	_
11-2	1847-1852	large	_
11-3	1853-1861	majority	_
11-4	1862-1864	of	_
11-5	1865-1869	CHRs	http://maven.renci.org/NeuroBridge/neurobridge#ChronicPain
11-6	1870-1873	was	_
11-7	1874-1879	naïve	_
11-8	1880-1882	to	_
11-9	1883-1895	psychotropic	_
11-10	1896-1906	medication	_
11-11	1907-1909	at	_
11-12	1910-1918	baseline	_
11-13	1919-1927	clinical	_
11-14	1928-1938	assessment	_
11-15	1939-1940	(	_
11-16	1941-1942	>	_
11-17	1943-1945	95	_
11-18	1946-1947	%	_
11-19	1948-1949	)	_
11-20	1950-1953	and	_
11-21	1954-1966	neuroimaging	_
11-22	1967-1968	(	_
11-23	1969-1970	>	_
11-24	1971-1973	80	_
11-25	1974-1975	%	_
11-26	1976-1977	)	_
11-27	1978-1979	.	_

12-1	1980-1992	Participants	_
12-2	1993-1997	were	_
12-3	1998-2007	recruited	_
12-4	2008-2010	at	_
12-5	2011-2014	the	_
12-6	2015-2023	Shanghai	_
12-7	2024-2030	Mental	_
12-8	2031-2037	Health	_
12-9	2038-2044	Center	_
12-10	2045-2046	(	_
12-11	2047-2051	SMHC	_
12-12	2052-2053	)	_
12-13	2054-2055	,	_
12-14	2056-2058	as	_
12-15	2059-2063	part	_
12-16	2064-2066	of	_
12-17	2067-2070	the	_
12-18	2071-2079	Shanghai	_
12-19	2080-2082	At	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-20	2083-2087	Risk	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-21	2088-2091	for	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-22	2092-2101	Psychosis	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-23	2102-2103	(	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-24	2104-2109	SHARP	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-25	2110-2111	)	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
12-26	2112-2119	program	_
12-27	2120-2121	.	_

13-1	2122-2126	This	_
13-2	2127-2138	NIMH-funded	_
13-3	2139-2144	study	_
13-4	2145-2147	is	_
13-5	2148-2149	a	_
13-6	2150-2163	collaboration	_
13-7	2164-2171	between	_
13-8	2172-2176	SMHC	_
13-9	2177-2178	,	_
13-10	2179-2186	Harvard	_
13-11	2187-2194	Medical	_
13-12	2195-2201	School	_
13-13	2202-2204	at	_
13-14	2205-2209	Beth	_
13-15	2210-2216	Israel	_
13-16	2217-2226	Deaconess	_
13-17	2227-2234	Medical	_
13-18	2235-2241	Center	_
13-19	2242-2243	(	_
13-20	2244-2249	BIDMC	_
13-21	2250-2251	)	_
13-22	2252-2255	and	_
13-23	2256-2263	Brigham	_
13-24	2264-2267	and	_
13-25	2268-2273	Women	_
13-26	2274-2275	’	_
13-27	2276-2277	s	_
13-28	2278-2286	Hospital	_
13-29	2287-2288	,	_
13-30	2289-2292	and	_
13-31	2293-2306	Massachusetts	_
13-32	2307-2316	Institute	_
13-33	2317-2319	of	_
13-34	2320-2330	Technology	_
13-35	2331-2332	(	_
13-36	2333-2338	study	_
13-37	2339-2346	details	_
13-38	2347-2356	including	_
13-39	2357-2362	power	_
13-40	2363-2371	analysis	_
13-41	2372-2375	and	_
13-42	2376-2388	in/exclusion	_
13-43	2389-2397	criteria	_
13-44	2398-2400	in	_
13-45	2401-2414	Supplementary	_
13-46	2415-2426	Information	_
13-47	2427-2430	1.1	_
13-48	2431-2432	)	_
13-49	2433-2434	.	_

14-1	2435-2438	The	_
14-2	2439-2444	study	_
14-3	2445-2448	was	_
14-4	2449-2457	approved	_
14-5	2458-2460	by	_
14-6	2461-2474	Institutional	_
14-7	2475-2481	Review	_
14-8	2482-2488	Boards	_
14-9	2489-2491	of	_
14-10	2492-2497	BIDMC	_
14-11	2498-2501	and	_
14-12	2502-2506	SMHC	_
14-13	2507-2508	.	_

15-1	2509-2512	All	_
15-2	2513-2521	subjects	_
15-3	2522-2524	or	_
15-4	2525-2530	their	_
15-5	2531-2536	legal	_
15-6	2537-2546	guardians	_
15-7	2547-2551	gave	_
15-8	2552-2559	written	_
15-9	2560-2568	informed	_
15-10	2569-2576	consent	_
15-11	2577-2578	.	_

16-1	2579-2584	Table	_
16-2	2585-2586	1	_
16-3	2587-2595	provides	_
16-4	2596-2607	demographic	_
16-5	2608-2611	and	_
16-6	2612-2620	clinical	_
16-7	2621-2636	characteristics	_
16-8	2637-2639	of	_
16-9	2640-2643	all	_
16-10	2644-2656	participants	_
16-11	2657-2658	.	_

17-1	2659-2667	Clinical	_
17-2	2668-2671	and	_
17-3	2672-2681	cognitive	_
17-4	2682-2692	assessment	_
17-5	2693-2702	Prodromal	_
17-6	2703-2711	symptoms	_
17-7	2712-2716	were	_
17-8	2717-2725	assessed	_
17-9	2726-2731	using	_
17-10	2732-2733	a	_
17-11	2734-2743	validated	_
17-12	2744-2751	Chinese	_
17-13	2752-2759	version	_
17-14	2760-2762	of	_
17-15	2763-2766	the	_
17-16	2767-2777	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-17	2778-2787	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-18	2788-2791	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-19	2792-2801	Prodromal	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-20	2802-2810	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-21	2811-2812	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-22	2813-2817	SIPS	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-23	2818-2819	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
17-24	2820-2821	.	_

18-1	2822-2827	Total	_
18-2	2828-2830	IQ	_
18-3	2831-2834	was	_
18-4	2835-2844	estimated	_
18-5	2845-2850	using	_
18-6	2851-2854	the	_
18-7	2855-2863	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-8	2864-2875	Abbreviated	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-9	2876-2881	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-10	2882-2884	of	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-11	2885-2897	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-12	2898-2899	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-13	2900-2904	WASI	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-14	2905-2906	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
18-15	2907-2908	.	_

19-1	2909-2919	Conversion	_
19-2	2920-2928	criteria	_
19-3	2929-2935	During	_
19-4	2936-2937	a	_
19-5	2938-2942	mean	_
19-6	2943-2944	(	_
19-7	2945-2947	sd	_
19-8	2948-2949	)	_
19-9	2950-2959	follow-up	_
19-10	2960-2962	of	_
19-11	2963-2966	392	_
19-12	2967-2968	(	_
19-13	2969-2971	77	_
19-14	2972-2973	)	_
19-15	2974-2978	days	_
19-16	2979-2980	,	_
19-17	2981-2983	23	_
19-18	2984-2988	CHRs	_
19-19	2989-2998	developed	_
19-20	2999-3008	psychosis	_
19-21	3009-3010	(	_
19-22	3011-3015	CHR+	_
19-23	3016-3017	)	_
19-24	3018-3019	,	_
19-25	3020-3025	while	_
19-26	3026-3029	135	_
19-27	3030-3033	did	_
19-28	3034-3037	not	_
19-29	3038-3039	(	_
19-30	3040-3044	CHR-	_
19-31	3045-3046	)	_
19-32	3047-3048	.	_

20-1	3049-3059	Conversion	_
20-2	3060-3062	to	_
20-3	3063-3072	psychosis	_
20-4	3073-3076	was	_
20-5	3077-3087	determined	_
20-6	3088-3093	using	_
20-7	3094-3097	the	_
20-8	3098-3102	SIPS	_
20-9	3103-3114	operational	_
20-10	3115-3125	definition	_
20-11	3126-3128	of	_
20-12	3129-3138	psychosis	_
20-13	3139-3144	onset	_
20-14	3145-3146	,	_
20-15	3147-3151	with	_
20-16	3152-3154	at	_
20-17	3155-3160	least	_
20-18	3161-3164	one	_
20-19	3165-3174	psychotic	_
20-20	3175-3180	level	_
20-21	3181-3188	symptom	_
20-22	3189-3190	(	_
20-23	3191-3196	rated	_
20-24	3197-3198	“	_
20-25	3199-3200	6	_
20-26	3201-3202	”	_
20-27	3203-3205	on	_
20-28	3206-3209	the	_
20-29	3210-3214	SIPS	_
20-30	3215-3223	positive	_
20-31	3224-3229	scale	_
20-32	3230-3231	)	_
20-33	3232-3236	with	_
20-34	3237-3243	either	_
20-35	3244-3254	sufficient	_
20-36	3255-3264	frequency	_
20-37	3265-3267	or	_
20-38	3268-3276	duration	_
20-39	3277-3278	.	_

21-1	3279-3282	For	_
21-2	3283-3287	CHR+	_
21-3	3288-3289	,	_
21-4	3290-3293	the	_
21-5	3294-3298	date	_
21-6	3299-3301	of	_
21-7	3302-3312	conversion	_
21-8	3313-3316	was	_
21-9	3317-3325	recorded	_
21-10	3326-3329	and	_
21-11	3330-3334	time	_
21-12	3335-3337	to	_
21-13	3338-3347	psychosis	_
21-14	3348-3356	computed	_
21-15	3357-3359	as	_
21-16	3360-3363	the	_
21-17	3364-3370	number	_
21-18	3371-3373	of	_
21-19	3374-3378	days	_
21-20	3379-3386	between	_
21-21	3387-3392	study	_
21-22	3393-3402	inclusion	_
21-23	3403-3406	and	_
21-24	3407-3416	psychosis	_
21-25	3417-3422	onset	_
21-26	3423-3424	.	_

22-1	3425-3430	Image	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-2	3431-3442	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-3	3443-3451	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-4	3452-3461	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-5	3462-3469	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-6	3470-3471	(	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-7	3472-3475	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-8	3476-3477	)	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
22-9	3478-3483	scans	_
22-10	3484-3488	were	_
22-11	3489-3497	acquired	_
22-12	3498-3500	on	_
22-13	3501-3502	a	_
22-14	3503-3505	3T	_
22-15	3506-3513	Siemens	_
22-16	3514-3516	MR	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
22-17	3517-3520	B17	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
22-18	3521-3522	(	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
22-19	3523-3528	Verio	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
22-20	3529-3530	)	_
22-21	3531-3537	system	_
22-22	3538-3539	,	_
22-23	3540-3550	32-channel	_
22-24	3551-3555	head	_
22-25	3556-3560	coil	_
22-26	3561-3563	at	_
22-27	3564-3567	the	_
22-28	3568-3572	SMHC	_
22-29	3573-3576	and	_
22-30	3577-3585	included	_
22-31	3586-3588	an	_
22-32	3589-3599	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
22-33	3600-3611	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-34	3612-3615	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-35	3616-3620	scan	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
22-36	3621-3622	(	_
22-37	3623-3630	MP-RAGE	_
22-38	3631-3632	;	_
22-39	3633-3640	TR=2300	_
22-40	3641-3643	ms	_
22-41	3644-3645	,	_
22-42	3646-3653	TE=2.96	_
22-43	3654-3656	ms	_
22-44	3657-3658	,	_
22-45	3659-3663	FA=9	_
22-46	3664-3670	degree	_
22-47	3671-3672	,	_
22-48	3673-3682	FOV=256mm	_
22-49	3683-3684	,	_
22-50	3685-3690	voxel	_
22-51	3691-3695	size	_
22-52	3696-3697	:	_
22-53	3698-3705	1×1×1mm	_
22-54	3706-3707	,	_
22-55	3708-3711	192	_
22-56	3712-3722	contiguous	_
22-57	3723-3731	sagittal	_
22-58	3732-3738	slices	_
22-59	3739-3740	,	_
22-60	3741-3749	duration	_
22-61	3750-3751	9	_
22-62	3752-3753	’	_
22-63	3754-3756	14	_
22-64	3757-3758	’	_
22-65	3759-3760	’	_
22-66	3761-3762	)	_
22-67	3763-3766	and	_
22-68	3767-3780	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-69	3781-3785	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-70	3786-3787	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-71	3788-3795	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-72	3796-3797	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-73	3798-3802	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-74	3803-3804	(	_
22-75	3805-3808	149	_
22-76	3809-3819	functional	_
22-77	3820-3827	volumes	_
22-78	3828-3829	;	_
22-79	3830-3837	TR=2500	_
22-80	3838-3840	ms	_
22-81	3841-3842	,	_
22-82	3843-3848	TE=30	_
22-83	3849-3851	ms	_
22-84	3852-3853	,	_
22-85	3854-3859	FA=90	_
22-86	3860-3866	degree	_
22-87	3867-3868	,	_
22-88	3869-3878	FOV=224mm	_
22-89	3879-3880	,	_
22-90	3881-3886	voxel	_
22-91	3887-3891	size	_
22-92	3892-3893	:	_
22-93	3894-3907	3.5×3.5×3.5mm	_
22-94	3908-3909	,	_
22-95	3910-3912	37	_
22-96	3913-3923	contiguous	_
22-97	3924-3929	axial	_
22-98	3930-3936	slices	_
22-99	3937-3938	,	_
22-100	3939-3947	duration	_
22-101	3948-3949	6	_
22-102	3950-3951	’	_
22-103	3952-3954	19	_
22-104	3955-3956	’	_
22-105	3957-3958	’	_
22-106	3959-3960	)	_
22-107	3961-3962	.	_

23-1	3963-3968	Image	_
23-2	3969-3982	preprocessing	_
23-3	3983-3989	Figure	_
23-4	3990-3991	1	_
23-5	3992-4000	provides	_
23-6	4001-4003	an	_
23-7	4004-4012	overview	_
23-8	4013-4015	of	_
23-9	4016-4019	all	_
23-10	4020-4028	analysis	_
23-11	4029-4034	steps	_
23-12	4035-4036	.	_

24-1	4037-4039	As	_
24-2	4040-4052	connectivity	_
24-3	4053-4056	and	_
24-4	4057-4067	connectome	_
24-5	4068-4075	metrics	_
24-6	4076-4079	are	_
24-7	4080-4089	sensitive	_
24-8	4090-4092	to	_
24-9	4093-4107	methodological	_
24-10	4108-4115	factors	_
24-11	4116-4125	including	_
24-12	4126-4131	image	_
24-13	4132-4145	preprocessing	_
24-14	4146-4149	and	_
24-15	4150-4154	node	_
24-16	4155-4164	selection	_
24-17	4165-4166	,	_
24-18	4167-4170	two	_
24-19	4171-4181	processing	_
24-20	4182-4189	streams	_
24-21	4190-4194	were	_
24-22	4195-4199	used	_
24-23	4200-4202	to	_
24-24	4203-4210	process	_
24-25	4211-4214	our	_
24-26	4215-4219	data	_
24-27	4220-4222	to	_
24-28	4223-4229	ensure	_
24-29	4230-4234	that	_
24-30	4235-4242	results	_
24-31	4243-4247	were	_
24-32	4248-4251	not	_
24-33	4252-4260	specific	_
24-34	4261-4263	to	_
24-35	4264-4267	any	_
24-36	4268-4271	one	_
24-37	4272-4283	methodology	_
24-38	4284-4285	(	_
24-39	4286-4292	Figure	_
24-40	4293-4295	1A	_
24-41	4296-4297	)	_
24-42	4298-4299	:	_
24-43	4300-4301	a	_
24-44	4302-4315	surface-based	_
24-45	4316-4322	method	_
24-46	4323-4324	,	_
24-47	4325-4328	the	_
24-48	4329-4336	results	_
24-49	4337-4339	of	_
24-50	4340-4345	which	_
24-51	4346-4349	are	_
24-52	4350-4359	presented	_
24-53	4360-4362	as	_
24-54	4363-4370	primary	_
24-55	4371-4379	findings	_
24-56	4380-4381	,	_
24-57	4382-4385	and	_
24-58	4386-4388	an	_
24-59	4389-4398	MNI-based	_
24-60	4399-4405	method	_
24-61	4406-4410	used	_
24-62	4411-4413	to	_
24-63	4414-4420	verify	_
24-64	4421-4428	primary	_
24-65	4429-4437	findings	_
24-66	4438-4439	.	_

25-1	4440-4445	Image	_
25-2	4446-4456	processing	_
25-3	4457-4459	is	_
25-4	4460-4469	described	_
25-5	4470-4472	in	_
25-6	4473-4479	detail	_
25-7	4480-4482	in	_
25-8	4483-4496	Supplementary	_
25-9	4497-4508	Information	_
25-10	4509-4512	1.2	_
25-11	4513-4514	.	_

26-1	4515-4522	Briefly	_
26-2	4523-4524	,	_
26-3	4525-4535	FreeSurfer	_
26-4	4536-4537	(	_
26-5	4538-4542	v6.0	_
26-6	4543-4544	)	_
26-7	4545-4548	and	_
26-8	4549-4553	CONN	_
26-9	4554-4555	(	_
26-10	4556-4560	v17d	_
26-11	4561-4562	)	_
26-12	4563-4571	software	_
26-13	4572-4576	were	_
26-14	4577-4581	used	_
26-15	4582-4584	to	_
26-16	4585-4595	preprocess	_
26-17	4596-4598	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
26-18	4599-4602	and	_
26-19	4603-4610	rs-fMRI	_
26-20	4611-4615	data	_
26-21	4616-4617	.	_

27-1	4618-4621	For	_
27-2	4622-4635	surface-based	_
27-3	4636-4646	processing	_
27-4	4647-4648	,	_
27-5	4649-4650	a	_
27-6	4651-4656	total	_
27-7	4657-4659	of	_
27-8	4660-4663	162	_
27-9	4664-4680	subject-specific	_
27-10	4681-4685	ROIs	_
27-11	4686-4693	derived	_
27-12	4694-4698	from	_
27-13	4699-4709	FreeSurfer	_
27-14	4710-4714	were	_
27-15	4715-4719	used	_
27-16	4720-4722	as	_
27-17	4723-4728	nodes	_
27-18	4729-4730	,	_
27-19	4731-4740	including	_
27-20	4741-4744	148	_
27-21	4745-4752	regions	_
27-22	4753-4763	comprising	_
27-23	4764-4767	the	_
27-24	4768-4777	Destrieux	_
27-25	4778-4783	Atlas	_
27-26	4784-4787	and	_
27-27	4788-4790	14	_
27-28	4791-4802	subcortical	_
27-29	4803-4813	structures	_
27-30	4814-4815	(	_
27-31	4816-4825	bilateral	_
27-32	4826-4834	thalamus	_
27-33	4835-4836	,	_
27-34	4837-4848	hippocampus	_
27-35	4849-4850	,	_
27-36	4851-4859	amygdala	_
27-37	4860-4861	,	_
27-38	4862-4869	nucleus	_
27-39	4870-4879	accumbens	_
27-40	4880-4881	,	_
27-41	4882-4889	caudate	_
27-42	4890-4897	nucleus	_
27-43	4898-4899	,	_
27-44	4900-4907	putamen	_
27-45	4908-4911	and	_
27-46	4912-4918	global	_
27-47	4919-4927	pallidus	_
27-48	4928-4929	)	_
27-49	4930-4931	.	_

28-1	4932-4935	For	_
28-2	4936-4945	MNI-based	_
28-3	4946-4956	processing	_
28-4	4957-4958	,	_
28-5	4959-4961	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
28-6	4962-4965	and	_
28-7	4966-4973	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
28-8	4974-4979	scans	_
28-9	4980-4984	were	_
28-10	4985-4995	normalized	_
28-11	4996-4998	to	_
28-12	4999-5002	MNI	_
28-13	5003-5008	space	_
28-14	5009-5012	and	_
28-15	5013-5016	the	_
28-16	5017-5031	Harvard-Oxford	_
28-17	5032-5037	Atlas	_
28-18	5038-5041	was	_
28-19	5042-5046	used	_
28-20	5047-5049	to	_
28-21	5050-5056	divide	_
28-22	5057-5060	the	_
28-23	5061-5069	cerebrum	_
28-24	5070-5074	into	_
28-25	5075-5076	a	_
28-26	5077-5082	total	_
28-27	5083-5085	of	_
28-28	5086-5089	105	_
28-29	5090-5095	brain	_
28-30	5096-5103	regions	_
28-31	5104-5105	,	_
28-32	5106-5115	including	_
28-33	5116-5118	91	_
28-34	5119-5127	cortical	_
28-35	5128-5133	brain	_
28-36	5134-5141	regions	_
28-37	5142-5145	and	_
28-38	5146-5149	the	_
28-39	5150-5154	same	_
28-40	5155-5157	14	_
28-41	5158-5169	subcortical	_
28-42	5170-5180	structures	_
28-43	5181-5182	.	_

29-1	5183-5191	Rigorous	_
29-2	5192-5198	motion	_
29-3	5199-5209	correction	_
29-4	5210-5213	and	_
29-5	5214-5222	artifact	_
29-6	5223-5230	removal	_
29-7	5231-5235	were	_
29-8	5236-5245	performed	_
29-9	5246-5248	to	_
29-10	5249-5253	deal	_
29-11	5254-5258	with	_
29-12	5259-5267	spurious	_
29-13	5268-5280	correlations	_
29-14	5281-5282	.	_

30-1	5283-5288	There	_
30-2	5289-5293	were	_
30-3	5294-5296	no	_
30-4	5297-5308	significant	_
30-5	5309-5326	group-differences	_
30-6	5327-5329	in	_
30-7	5330-5336	motion	_
30-8	5337-5347	parameters	_
30-9	5348-5350	or	_
30-10	5351-5354	the	_
30-11	5355-5361	number	_
30-12	5362-5364	of	_
30-13	5365-5373	rejected	_
30-14	5374-5378	fMRI	_
30-15	5379-5386	volumes	_
30-16	5387-5388	(	_
30-17	5389-5402	Supplementary	_
30-18	5403-5414	Information	_
30-19	5415-5418	1.2	_
30-20	5419-5420	)	_
30-21	5421-5422	.	_

31-1	5423-5433	Functional	_
31-2	5434-5444	connectome	_
31-3	5445-5459	reconstruction	_
31-4	5460-5461	A	_
31-5	5462-5472	functional	_
31-6	5473-5483	connectome	_
31-7	5484-5487	was	_
31-8	5488-5499	constructed	_
31-9	5500-5503	for	_
31-10	5504-5508	each	_
31-11	5509-5520	participant	_
31-12	5521-5522	,	_
31-13	5523-5533	consisting	_
31-14	5534-5536	of	_
31-15	5537-5540	162	_
31-16	5541-5557	subject-specific	_
31-17	5558-5559	(	_
31-18	5560-5562	or	_
31-19	5563-5566	105	_
31-20	5567-5578	atlas-based	_
31-21	5579-5580	)	_
31-22	5581-5586	nodes	_
31-23	5587-5599	representing	_
31-24	5600-5603	the	_
31-25	5604-5618	aforementioned	_
31-26	5619-5624	brain	_
31-27	5625-5632	regions	_
31-28	5633-5634	.	_

32-1	5635-5638	The	_
32-2	5639-5644	level	_
32-3	5645-5647	of	_
32-4	5648-5658	functional	_
32-5	5659-5671	connectivity	_
32-6	5672-5679	between	_
32-7	5680-5684	each	_
32-8	5685-5689	node	_
32-9	5690-5694	pair	_
32-10	5695-5698	was	_
32-11	5699-5707	computed	_
32-12	5708-5710	as	_
32-13	5711-5714	the	_
32-14	5715-5725	normalized	_
32-15	5726-5733	z-score	_
32-16	5734-5736	of	_
32-17	5737-5740	the	_
32-18	5741-5748	Pearson	_
32-19	5749-5750	’	_
32-20	5751-5752	s	_
32-21	5753-5764	correlation	_
32-22	5765-5772	between	_
32-23	5773-5776	the	_
32-24	5777-5792	noise-corrected	_
32-25	5793-5803	timeseries	_
32-26	5804-5806	of	_
32-27	5807-5811	each	_
32-28	5812-5816	pair	_
32-29	5817-5819	of	_
32-30	5820-5825	brain	_
32-31	5826-5833	regions	_
32-32	5834-5837	and	_
32-33	5838-5844	stored	_
32-34	5845-5847	in	_
32-35	5848-5849	a	_
32-36	5850-5860	functional	_
32-37	5861-5873	connectivity	_
32-38	5874-5880	matrix	_
32-39	5881-5882	(	_
32-40	5883-5889	Figure	_
32-41	5890-5892	1B	_
32-42	5893-5894	)	_
32-43	5895-5896	.	_

33-1	5897-5904	Modular	_
33-2	5905-5917	organization	_
33-3	5918-5920	of	_
33-4	5921-5924	the	_
33-5	5925-5935	functional	_
33-6	5936-5946	connectome	_
33-7	5947-5954	Various	_
33-8	5955-5962	methods	_
33-9	5963-5968	exist	_
33-10	5969-5971	to	_
33-11	5972-5979	examine	_
33-12	5980-5983	the	_
33-13	5984-5991	modular	_
33-14	5992-6004	organization	_
33-15	6005-6007	of	_
33-16	6008-6015	complex	_
33-17	6016-6024	networks	_
33-18	6025-6026	.	_

34-1	6027-6031	Here	_
34-2	6032-6033	,	_
34-3	6034-6036	we	_
34-4	6037-6040	use	_
34-5	6041-6044	the	_
34-6	6045-6052	Louvain	_
34-7	6053-6062	community	_
34-8	6063-6072	detection	_
34-9	6073-6079	method	_
34-10	6080-6081	(	_
34-11	6082-6087	https	_
34-12	6088-6089	:	_
34-13	6090-6121	//sites.google.com/site/bctnet/	_
34-14	6122-6123	)	_
34-15	6124-6125	,	_
34-16	6126-6131	which	_
34-17	6132-6142	partitions	_
34-18	6143-6144	a	_
34-19	6145-6152	network	_
34-20	6153-6155	so	_
34-21	6156-6158	as	_
34-22	6159-6161	to	_
34-23	6162-6170	maximize	_
34-24	6171-6177	metric	_
34-25	6178-6179	Q	_
34-26	6180-6181	,	_
34-27	6182-6194	representing	_
34-28	6195-6198	the	_
34-29	6199-6207	strength	_
34-30	6208-6210	of	_
34-31	6211-6216	edges	_
34-32	6217-6223	inside	_
34-33	6224-6235	communities	_
34-34	6236-6244	relative	_
34-35	6245-6247	to	_
34-36	6248-6253	edges	_
34-37	6254-6261	between	_
34-38	6262-6273	communities	_
34-39	6274-6275	.	_

35-1	6276-6279	The	_
35-2	6280-6286	method	_
35-3	6287-6289	is	_
35-4	6290-6298	suitable	_
35-5	6299-6302	for	_
35-6	6303-6313	functional	_
35-7	6314-6324	connectome	_
35-8	6325-6333	analysis	_
35-9	6334-6336	as	_
35-10	6337-6339	it	_
35-11	6340-6343	can	_
35-12	6344-6348	take	_
35-13	6349-6353	both	_
35-14	6354-6362	positive	_
35-15	6363-6366	and	_
35-16	6367-6375	negative	_
35-17	6376-6380	edge	_
35-18	6381-6388	weights	_
35-19	6389-6390	(	_
35-20	6391-6395	i.e.	_
35-21	6396-6397	,	_
35-22	6398-6410	connectivity	_
35-23	6411-6420	estimates	_
35-24	6421-6422	)	_
35-25	6423-6427	into	_
35-26	6428-6435	account	_
35-27	6436-6443	without	_
35-28	6444-6453	requiring	_
35-29	6454-6456	an	_
35-30	6457-6466	arbitrary	_
35-31	6467-6479	connectivity	_
35-32	6480-6489	threshold	_
35-33	6490-6491	.	_

36-1	6492-6506	Group-networks	_
36-2	6507-6508	.	_

37-1	6509-6511	As	_
37-2	6512-6513	a	_
37-3	6514-6519	first	_
37-4	6520-6524	step	_
37-5	6525-6527	to	_
37-6	6528-6534	assess	_
37-7	6535-6538	the	_
37-8	6539-6546	modular	_
37-9	6547-6559	organization	_
37-10	6560-6562	of	_
37-11	6563-6566	the	_
37-12	6567-6577	functional	_
37-13	6578-6588	connectome	_
37-14	6589-6590	,	_
37-15	6591-6594	one	_
37-16	6595-6609	group-averaged	_
37-17	6610-6620	functional	_
37-18	6621-6628	network	_
37-19	6629-6632	was	_
37-20	6633-6644	constructed	_
37-21	6645-6648	for	_
37-22	6649-6651	HC	_
37-23	6652-6653	,	_
37-24	6654-6658	CHR-	_
37-25	6659-6660	,	_
37-26	6661-6664	and	_
37-27	6665-6669	CHR+	_
37-28	6670-6676	groups	_
37-29	6677-6678	.	_

38-1	6679-6683	Each	_
38-2	6684-6697	group-network	_
38-3	6698-6699	’	_
38-4	6700-6701	s	_
38-5	6702-6709	modular	_
38-6	6710-6722	organization	_
38-7	6723-6726	was	_
38-8	6727-6735	assessed	_
38-9	6736-6741	using	_
38-10	6742-6745	the	_
38-11	6746-6753	Louvain	_
38-12	6754-6760	method	_
38-13	6761-6762	.	_

39-1	6763-6765	As	_
39-2	6766-6769	the	_
39-3	6770-6779	algorithm	_
39-4	6780-6788	searches	_
39-5	6789-6792	for	_
39-6	6793-6797	high	_
39-7	6798-6808	modularity	_
39-8	6809-6819	partitions	_
39-9	6820-6822	in	_
39-10	6823-6824	a	_
39-11	6825-6834	heuristic	_
39-12	6835-6842	fashion	_
39-13	6843-6844	,	_
39-14	6845-6854	resulting	_
39-15	6855-6865	partitions	_
39-16	6866-6872	differ	_
39-17	6873-6881	slightly	_
39-18	6882-6886	from	_
39-19	6887-6890	run	_
39-20	6891-6893	to	_
39-21	6894-6897	run	_
39-22	6898-6899	.	_

40-1	6900-6909	Therefore	_
40-2	6910-6911	,	_
40-3	6912-6915	the	_
40-4	6916-6925	algorithm	_
40-5	6926-6929	was	_
40-6	6930-6933	run	_
40-7	6934-6940	10,000	_
40-8	6941-6946	times	_
40-9	6947-6950	for	_
40-10	6951-6955	each	_
40-11	6956-6969	group-network	_
40-12	6970-6973	and	_
40-13	6974-6977	the	_
40-14	6978-6987	partition	_
40-15	6988-6998	associated	_
40-16	6999-7003	with	_
40-17	7004-7007	the	_
40-18	7008-7015	highest	_
40-19	7016-7021	level	_
40-20	7022-7024	of	_
40-21	7025-7026	Q	_
40-22	7027-7035	selected	_
40-23	7036-7037	(	_
40-24	7038-7044	Figure	_
40-25	7045-7047	1C	_
40-26	7048-7049	)	_
40-27	7050-7051	.	_

41-1	7052-7053	A	_
41-2	7054-7063	consensus	_
41-3	7064-7074	similarity	_
41-4	7075-7081	method	_
41-5	7082-7085	was	_
41-6	7086-7090	used	_
41-7	7091-7093	as	_
41-8	7094-7096	an	_
41-9	7097-7108	alternative	_
41-10	7109-7115	method	_
41-11	7116-7118	to	_
41-12	7119-7125	select	_
41-13	7126-7133	modular	_
41-14	7134-7144	partitions	_
41-15	7145-7148	for	_
41-16	7149-7153	both	_
41-17	7154-7159	group	_
41-18	7160-7163	and	_
41-19	7164-7174	individual	_
41-20	7175-7183	networks	_
41-21	7184-7185	(	_
41-22	7186-7199	Supplementary	_
41-23	7200-7211	Information	_
41-24	7212-7215	1.3	_
41-25	7216-7217	)	_
41-26	7218-7219	.	_

42-1	7220-7230	Individual	_
42-2	7231-7239	subjects	_
42-3	7240-7241	.	_

43-1	7242-7248	Second	_
43-2	7249-7250	,	_
43-3	7251-7254	the	_
43-4	7255-7262	Louvain	_
43-5	7263-7272	algorithm	_
43-6	7273-7276	was	_
43-7	7277-7284	applied	_
43-8	7285-7287	to	_
43-9	7288-7298	individual	_
43-10	7299-7309	connectome	_
43-11	7310-7325	reconstructions	_
43-12	7326-7327	.	_

44-1	7328-7330	To	_
44-2	7331-7337	assess	_
44-3	7338-7341	how	_
44-4	7342-7349	similar	_
44-5	7350-7353	the	_
44-6	7354-7361	modular	_
44-7	7362-7374	organization	_
44-8	7375-7377	of	_
44-9	7378-7382	each	_
44-10	7383-7393	individual	_
44-11	7394-7401	network	_
44-12	7402-7405	was	_
44-13	7406-7408	to	_
44-14	7409-7411	an	_
44-15	7412-7419	average	_
44-16	7420-7427	healthy	_
44-17	7428-7435	network	_
44-18	7436-7437	,	_
44-19	7438-7445	network	_
44-20	7446-7456	partitions	_
44-21	7457-7459	of	_
44-22	7460-7470	individual	_
44-23	7471-7479	subjects	_
44-24	7480-7484	were	_
44-25	7485-7493	compared	_
44-26	7494-7496	to	_
44-27	7497-7500	the	_
44-28	7501-7515	group-averaged	_
44-29	7516-7518	HC	_
44-30	7519-7526	network	_
44-31	7527-7532	using	_
44-32	7533-7536	the	_
44-33	7537-7541	Rand	_
44-34	7542-7552	similarity	_
44-35	7553-7564	coefficient	_
44-36	7565-7566	(	_
44-37	7567-7569	SR	_
44-38	7570-7571	)	_
44-39	7572-7573	,	_
44-40	7574-7583	providing	_
44-41	7584-7586	an	_
44-42	7587-7596	intuitive	_
44-43	7597-7604	measure	_
44-44	7605-7606	(	_
44-45	7607-7614	between	_
44-46	7615-7616	0	_
44-47	7617-7620	and	_
44-48	7621-7622	1	_
44-49	7623-7624	)	_
44-50	7625-7627	of	_
44-51	7628-7631	the	_
44-52	7632-7642	similarity	_
44-53	7643-7650	between	_
44-54	7651-7654	two	_
44-55	7655-7665	partitions	_
44-56	7666-7667	(	_
44-57	7668-7675	details	_
44-58	7676-7678	in	_
44-59	7679-7692	Supplementary	_
44-60	7693-7704	Information	_
44-61	7705-7708	1.3	_
44-62	7709-7710	)	_
44-63	7711-7712	.	_

45-1	7713-7720	Network	_
45-2	7721-7731	resolution	_
45-3	7732-7741	parameter	_
45-4	7742-7743	γ	_
45-5	7744-7747	was	_
45-6	7748-7751	set	_
45-7	7752-7754	to	_
45-8	7755-7758	1.5	_
45-9	7759-7760	,	_
45-10	7761-7763	in	_
45-11	7764-7769	order	_
45-12	7770-7772	to	_
45-13	7773-7781	identify	_
45-14	7782-7786	more	_
45-15	7787-7799	fine-grained	_
45-16	7800-7807	modules	_
45-17	7808-7813	while	_
45-18	7814-7817	not	_
45-19	7818-7831	overinflating	_
45-20	7832-7835	the	_
45-21	7836-7841	total	_
45-22	7842-7848	number	_
45-23	7849-7851	of	_
45-24	7852-7859	modules	_
45-25	7860-7861	,	_
45-26	7862-7864	as	_
45-27	7865-7869	this	_
45-28	7870-7875	would	_
45-29	7876-7882	hamper	_
45-30	7883-7894	comparisons	_
45-31	7895-7897	of	_
45-32	7898-7905	network	_
45-33	7906-7916	partitions	_
45-34	7917-7918	.	_

46-1	7919-7921	In	_
46-2	7922-7930	addition	_
46-3	7931-7932	,	_
46-4	7933-7940	modular	_
46-5	7941-7953	organization	_
46-6	7954-7957	was	_
46-7	7958-7966	examined	_
46-8	7967-7973	across	_
46-9	7974-7975	a	_
46-10	7976-7981	range	_
46-11	7982-7984	of	_
46-12	7985-7986	γ	_
46-13	7987-7988	(	_
46-14	7989-8002	Supplementary	_
46-15	8003-8014	Information	_
46-16	8015-8018	1.3	_
46-17	8019-8020	)	_
46-18	8021-8022	.	_

47-1	8023-8038	Region-specific	_
47-2	8039-8050	alterations	_
47-3	8051-8053	in	_
47-4	8054-8061	modular	_
47-5	8062-8072	connectome	_
47-6	8073-8085	organization	_
47-7	8086-8088	As	_
47-8	8089-8091	an	_
47-9	8092-8103	exploratory	_
47-10	8104-8112	analysis	_
47-11	8113-8115	to	_
47-12	8116-8122	assess	_
47-13	8123-8128	which	_
47-14	8129-8134	brain	_
47-15	8135-8142	regions	_
47-16	8143-8146	are	_
47-17	8147-8151	most	_
47-18	8152-8160	abnormal	_
47-19	8161-8163	in	_
47-20	8164-8169	terms	_
47-21	8170-8172	of	_
47-22	8173-8179	module	_
47-23	8180-8190	assignment	_
47-24	8191-8193	in	_
47-25	8194-8198	CHR+	_
47-26	8199-8205	versus	_
47-27	8206-8210	CHR-	_
47-28	8211-8212	,	_
47-29	8213-8223	individual	_
47-30	8224-8232	networks	_
47-31	8233-8237	were	_
47-32	8238-8243	again	_
47-33	8244-8252	compared	_
47-34	8253-8255	to	_
47-35	8256-8259	the	_
47-36	8260-8262	HC	_
47-37	8263-8270	network	_
47-38	8271-8272	,	_
47-39	8273-8276	now	_
47-40	8277-8288	determining	_
47-41	8289-8292	for	_
47-42	8293-8297	each	_
47-43	8298-8302	node	_
47-44	8303-8304	i	_
47-45	8305-8307	in	_
47-46	8308-8311	the	_
47-47	8312-8319	network	_
47-48	8320-8323	the	_
47-49	8324-8332	fraction	_
47-50	8333-8335	of	_
47-51	8336-8347	neighboring	_
47-52	8348-8353	nodes	_
47-53	8354-8358	with	_
47-54	8359-8364	equal	_
47-55	8365-8371	module	_
47-56	8372-8382	assignment	_
47-57	8383-8384	(	_
47-58	8385-8392	details	_
47-59	8393-8395	in	_
47-60	8396-8409	Supplementary	_
47-61	8410-8421	Information	_
47-62	8422-8425	1.3	_
47-63	8426-8427	)	_
47-64	8428-8429	.	_

48-1	8430-8434	Code	_
48-2	8435-8447	availability	_
48-3	8448-8451	All	_
48-4	8452-8457	image	_
48-5	8458-8468	processing	_
48-6	8469-8472	and	_
48-7	8473-8478	graph	_
48-8	8479-8487	analyses	_
48-9	8488-8492	were	_
48-10	8493-8502	performed	_
48-11	8503-8508	using	_
48-12	8509-8515	freely	_
48-13	8516-8525	available	_
48-14	8526-8534	software	_
48-15	8535-8536	.	_

49-1	8537-8544	Version	_
49-2	8545-8548	and	_
49-3	8549-8555	access	_
49-4	8556-8563	details	_
49-5	8564-8567	are	_
49-6	8568-8576	provided	_
49-7	8577-8579	in	_
49-8	8580-8593	Supplementary	_
49-9	8594-8605	Information	_
49-10	8606-8609	1.2	_
49-11	8610-8613	and	_
49-12	8614-8617	1.3	_
49-13	8618-8619	.	_

50-1	8620-8631	Statistical	_
50-2	8632-8640	analysis	_
50-3	8641-8646	Group	_
50-4	8647-8655	analysis	_
50-5	8656-8657	.	_

51-1	8658-8666	Analysis	_
51-2	8667-8669	of	_
51-3	8670-8680	Covariance	_
51-4	8681-8682	(	_
51-5	8683-8689	ANCOVA	_
51-6	8690-8691	)	_
51-7	8692-8695	was	_
51-8	8696-8700	used	_
51-9	8701-8703	to	_
51-10	8704-8711	compare	_
51-11	8712-8714	SR	_
51-12	8715-8720	among	_
51-13	8721-8728	subject	_
51-14	8729-8735	groups	_
51-15	8736-8737	.	_

52-1	8738-8749	Assumptions	_
52-2	8750-8752	of	_
52-3	8753-8762	normality	_
52-4	8763-8766	and	_
52-5	8767-8778	homogeneity	_
52-6	8779-8781	of	_
52-7	8782-8790	variance	_
52-8	8791-8795	were	_
52-9	8796-8799	met	_
52-10	8800-8801	(	_
52-11	8802-8815	Supplementary	_
52-12	8816-8827	Information	_
52-13	8828-8831	1.4	_
52-14	8832-8833	)	_
52-15	8834-8835	.	_

53-1	8836-8839	Age	_
53-2	8840-8841	,	_
53-3	8842-8845	sex	_
53-4	8846-8847	,	_
53-5	8848-8851	and	_
53-6	8852-8855	the	_
53-7	8856-8862	number	_
53-8	8863-8865	of	_
53-9	8866-8874	rejected	_
53-10	8875-8879	fMRI	_
53-11	8880-8887	volumes	_
53-12	8888-8892	were	_
53-13	8893-8901	included	_
53-14	8902-8904	in	_
53-15	8905-8908	the	_
53-16	8909-8914	model	_
53-17	8915-8917	as	_
53-18	8918-8928	covariates	_
53-19	8929-8930	,	_
53-20	8931-8934	and	_
53-21	8935-8950	group-covariate	_
53-22	8951-8963	interactions	_
53-23	8964-8968	were	_
53-24	8969-8977	assessed	_
53-25	8978-8979	.	_

54-1	8980-8990	Medication	_
54-2	8991-8997	status	_
54-3	8998-9001	was	_
54-4	9002-9010	included	_
54-5	9011-9013	as	_
54-6	9014-9015	a	_
54-7	9016-9025	covariate	_
54-8	9026-9028	of	_
54-9	9029-9041	non-interest	_
54-10	9042-9044	as	_
54-11	9045-9046	a	_
54-12	9047-9055	minority	_
54-13	9056-9058	of	_
54-14	9059-9063	CHRs	_
54-15	9064-9065	(	_
54-16	9066-9067	<	_
54-17	9068-9070	20	_
54-18	9071-9072	%	_
54-19	9073-9074	)	_
54-20	9075-9079	were	_
54-21	9080-9082	on	_
54-22	9083-9095	psychotropic	_
54-23	9096-9106	medication	_
54-24	9107-9109	by	_
54-25	9110-9113	the	_
54-26	9114-9118	time	_
54-27	9119-9121	of	_
54-28	9122-9130	scanning	_
54-29	9131-9132	.	_

55-1	9133-9148	Region-specific	_
55-2	9149-9156	metrics	_
55-3	9157-9161	were	_
55-4	9162-9170	analyzed	_
55-5	9171-9176	using	_
55-6	9177-9180	the	_
55-7	9181-9185	same	_
55-8	9186-9192	ANCOVA	_
55-9	9193-9198	model	_
55-10	9199-9200	,	_
55-11	9201-9209	applying	_
55-12	9210-9224	FDR-correction	_
55-13	9225-9226	(	_
55-14	9227-9228	q	_
55-15	9229-9230	=	_
55-16	9231-9234	.05	_
55-17	9235-9236	)	_
55-18	9237-9239	to	_
55-19	9240-9247	account	_
55-20	9248-9251	for	_
55-21	9252-9260	multiple	_
55-22	9261-9272	comparisons	_
55-23	9273-9274	.	_

56-1	9275-9289	Psychosis-free	_
56-2	9290-9298	survival	_
56-3	9299-9307	analysis	_
56-4	9308-9309	.	_

57-1	9310-9312	To	_
57-2	9313-9322	determine	_
57-3	9323-9330	whether	_
57-4	9331-9339	abnormal	_
57-5	9340-9347	modular	_
57-6	9348-9358	connectome	_
57-7	9359-9371	organization	_
57-8	9372-9374	at	_
57-9	9375-9383	baseline	_
57-10	9384-9393	predicted	_
57-11	9394-9404	conversion	_
57-12	9405-9407	to	_
57-13	9408-9417	psychosis	_
57-14	9418-9419	,	_
57-15	9420-9424	CHRs	_
57-16	9425-9429	were	_
57-17	9430-9437	divided	_
57-18	9438-9440	by	_
57-19	9441-9447	median	_
57-20	9448-9453	split	_
57-21	9454-9458	into	_
57-22	9459-9462	two	_
57-23	9463-9469	groups	_
57-24	9470-9474	with	_
57-25	9475-9480	above	_
57-26	9481-9484	and	_
57-27	9485-9498	below-average	_
57-28	9499-9501	SR	_
57-29	9502-9503	,	_
57-30	9504-9514	reflecting	_
57-31	9515-9521	normal	_
57-32	9522-9525	and	_
57-33	9526-9534	abnormal	_
57-34	9535-9542	modular	_
57-35	9543-9555	organization	_
57-36	9556-9568	respectively	_
57-37	9569-9570	.	_

58-1	9571-9577	Kaplan	_
58-2	9578-9583	Meier	_
58-3	9584-9592	analysis	_
58-4	9593-9596	was	_
58-5	9597-9601	used	_
58-6	9602-9604	to	_
58-7	9605-9611	assess	_
58-8	9612-9626	psychosis-free	_
58-9	9627-9635	survival	_
58-10	9636-9639	for	_
58-11	9640-9644	each	_
58-12	9645-9650	group	_
58-13	9651-9652	.	_

59-1	9653-9661	Survival	_
59-2	9662-9671	functions	_
59-3	9672-9676	were	_
59-4	9677-9685	compared	_
59-5	9686-9691	using	_
59-6	9692-9700	log-rank	_
59-7	9701-9706	tests	_
59-8	9707-9708	.	_

60-1	9709-9712	Cox	_
60-2	9713-9723	regression	_
60-3	9724-9732	analysis	_
60-4	9733-9736	was	_
60-5	9737-9741	used	_
60-6	9742-9744	to	_
60-7	9745-9751	assess	_
60-8	9752-9755	how	_
60-9	9756-9764	baseline	_
60-10	9765-9772	modular	_
60-11	9773-9785	organization	_
60-12	9786-9789	and	_
60-13	9790-9798	clinical	_
60-14	9799-9814	characteristics	_
60-15	9815-9816	(	_
60-16	9817-9821	i.e.	_
60-17	9822-9823	,	_
60-18	9824-9827	age	_
60-19	9828-9829	,	_
60-20	9830-9833	sex	_
60-21	9834-9835	,	_
60-22	9836-9838	IQ	_
60-23	9839-9840	,	_
60-24	9841-9845	SIPS	_
60-25	9846-9854	symptoms	_
60-26	9855-9856	,	_
60-27	9857-9860	and	_
60-28	9861-9864	GAF	_
60-29	9865-9876	functioning	_
60-30	9877-9878	)	_
60-31	9879-9888	predicted	_
60-32	9889-9893	time	_
60-33	9894-9896	to	_
60-34	9897-9907	conversion	_
60-35	9908-9909	.	_

